Research programme: eptacog alfa inhalation - Savara Pharmaceuticals

Drug Profile

Research programme: eptacog alfa inhalation - Savara Pharmaceuticals

Alternative Names: Recombinant FVIIa inhalation - Serendex; Recombinant human factor VIIa inhalation - Serendex; rhFVIIa inhalation - Serendex

Latest Information Update: 20 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CMC Biologics
  • Developer Serendex Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants; Factor X stimulants; Haemostasis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 18 Jul 2016 Serendex Pharmaceuticals has been acquired and merged into Savara Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for research development in Haemorrhage in Denmark (Inhalation, Inhalant)
  • 21 Jun 2016 Savara Pharmaceuticals acquires eptacog alfa inhalation from Serendex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top